

15th September 2026

Eastbourne District General Hospital

Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500
Website: www.esht.nhs.uk

Further to your recent request for information made under the Freedom of Information Act (FOIA) 2000, I now set out our answers to your specific questions, and any clarifications sought and provided, as follows:

- 1) **Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.**

There were 195 patients. Please note that this number is lower than the total number of patients provided in response to question 2 (which is 199). This is because some patients switched treatments during the past six months.

- 2) **Of the multiple myeloma patients over the past 6 months, how many were treated with the following:**

• Belantamab Mafodotin [Blenrep]	4
• Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone	0
• Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone	1
• Bortezomib [Velcade]	0
• Bortezomib [Velcade] + Dexamethasone	0
• Bortezomib [Velcade] + Melphalan + Prednisolone/Dexamethasone (VMp or VCd)	0
• Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD)	0
• Carfilzomib [Kyprolis] + Dexamethasone	0
• Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd)	1
• Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd)	23
• Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd)	14
• Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd)	33
• Daratumumab [Darzalex] monotherapy	5
• Elranatamab	13
• Idecabtagene vicleucel [Abecma]	0

• Isatuximab [Sarclisa] subcutaneous injection + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd)	0
• Isatuximab [Sarclisa] + Pomalidomide [Imnovid] + Dexamethasone (IsaPd)	4
• Ixazomib [Ninlaro] + Lenalidomide [Revlimid] + Dexamethasone (IRd)	12
• Lenalidomide [Revlimid] + Dexamethasone	0
• Lenalidomide [Revlimid] monotherapy	60
• Panobinostat + Bortezomib + Dexamethasone	0
• Pomalidomide [Imnovid] + Dexamethasone	1
• Selinexor + Bortezomib [Velcade] + Dexamethasone	2
• Selinexor + Dexamethasone	0
• Talquetamab	3
• Teclistamab [Tecvayli]	0
• Any other systemic anti-cancer therapy for Multiple Myeloma Only [please specify]	23

3) In the last 6 months, how many patients have been initiated* on the following regimens?

• Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone	0
• Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone	0
• Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD)	0
• Carfilzomib [Kyprolis] + Dexamethasone	0
• Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd)	0
• Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd)	0
• Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd)	6
• Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd)	8
• Isatuximab [Sarclisa] subcutaneous injection + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd)	0
• Lenalidomide [Revlimid] monotherapy	2
• Lenalidomide [Revlimid] + Dexamethasone	0
• Selinexor + Bortezomib [Velcade] + Dexamethasone	0
• Selinexor + Dexamethasone	0
• Any other systemic anti-cancer therapy for Multiple Myeloma Only [please specify]	5

*Patients are considered initiated if they have not received any of the drugs in the named regimen (either alone or in combination) in the 6 months prior to initiation.

4) In the last 6 months, how many patients have received the following second-line treatment?

- Lenalidomide [Revlimid] + Dexamethasone

0.

5) Does your trust participate in any clinical trials for multiple myeloma? If so, please provide the name of each trial, and the number of patients taking part.

East Sussex Healthcare NHS Trust (ESHT) has the following academic clinical trial open:

RADAR (UK-MRA Myeloma XV)
Risk-Adapted therapy Directed According to Response comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma (NDMM) suitable for stem cell transplant (TE)
Recruits – 4. Closed to recruitment 09.03.2026.

ESHT has the following three commercial clinical trials open:

MM32-Ph3 C1071032:
A Phase 3, Open-Label Study Of Elranatamab Monotherapy Versus Elotuzumab, Pomalidomide, Dexamethasone (Epd) Or Pomalidomide, Bortezomib, Dexamethasone (Pvd) Or Carfilzomib, Dexamethasone (Kd) In Participants With Relapsed/Refractory Multiple Myeloma Who Received Prior Anti-Cd38 Directed Therapy.
Participants Recruited: 1

Study Title:
MagnetisMM-16: An International, Multicenter, Non-Interventional Post-Authorization Safety Study (PASS) to Evaluate the Effectiveness and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated in Real-World Settings.
IRAS No: 340997
Participants recruited: 6

Study Title: A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity. The Talisman Study.
IRAS No: 1009729
Participants recruited: 2

I trust this information is helpful in its detail or explanation however, if you are dissatisfied with the response, then you have the right to request an internal review. If you wish to seek an internal review, please write to the Freedom of Information Team at esh-tr.foi@nhs.net quoting the above FOI reference number, within 40 working days. Please note the Trust is not obliged to accept a request for an internal review after this time period.

Yours faithfully

Freedom of Information (FOI) Team
East Sussex Healthcare NHS Trust
0300 131 4716
Core Hours of Business: Monday to Friday 9.00am to 4.00pm